Open-label study of tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants previously treated for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with CEACAM5-positive tumors
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Ramucirumab (Primary) ; Tusamitamab ravtansine (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARMEN-GC01
- Sponsors Sanofi
- 04 Dec 2023 Planned End Date changed from 13 Oct 2023 to 28 Jun 2024.
- 18 Aug 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 06 Jul 2023 Planned End Date changed from 29 Sep 2023 to 13 Oct 2023.